YK11 is a unique compound that falls within several definitional classes. While its primary mechanism of building muscle is operating in an analogous fashion to a traditional DHT compound, it also reduces myostatin. It does this by increasing endogenous production of follistatin. Follistatin is an activin-binding protein is a protein that in humans is encoded by the FST gene. It is is an autocrine glycoprotein that is expressed in nearly all tissues. Follistatin inhibits myotstatin proliferation, a protein that sets a ceiling on muscle growth. YK-11 then raises the user’s growth potential from every other compound they take with it. Though when taken alone it will will still build substantial size and strength.
In a recent studies dihydrotestosterone (DHT) demonstrated greater capacity to increase force production in fast contracting muscles than testosterone. These findings led us to suggest that DHT may be a better muscle building hormone than testosterone. In the study of the effects of these hormones on amino acid transport in the fast and slow contracting skeletal muscle fibre bundles of mince, results show that DHT increases protein synthesis and the transport of essential amino acids into fast contracting muscle fibre bundles at a greater rate than testosterone. Moreover, YK-11 has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard.
YK-11 also promotes osteoblast proliferation and differentiation, and increases ALP activity (a marker of osteoblastic maturation) and calcium deposits. Similar to DHT, this activity may be mediated by the non-genomic action of androgen receptors. Thus, YK11 is useful as a potential anabolic SARM for androgen deficiency related diseases in men, such as osteoporosis.